Abstract:We recently read the article by Tian et al with great interest.1 In their research, the authors compared the prognosis of patients with gastric and gastroesophageal junction adenocarcinoma who received perioperative chemoradiotherapy (PCRT) with those who received perioperative chemotherapy (POC) alone. The authors found that the addition of preoperative radiotherapy to POC appears to be associated with an increased risk of death in both the gastric and gastroesophageal junction adenocarcinoma subgroups. However, by reviewing previous studies and conducting an external validation based on the Surveillance, Epidemiology, and End Results (SEER) database, we found some contradicting results. Thus, we believe more caution should be exercised regarding any conclusions that additional radiotherapy increased the risk of death. In the majority of previous studies, a similar prognosis was demonstrated between the PCRT and the POC groups,2-4 a finding that contradicts the results published by Tian et al.1 Furthermore, if we focused on the patient with a T3 to T4 tumor, PCRT might have a positive influence on survival. For example, Stahl et al reported that in the Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET) trial (in which only patients with T3-T4 tumors were included),5 the PCRT group had a significantly improved progression-free survival (hazard ratio [HR], 0.37; P = .01) and the overall survival (OS) also demonstrated a positive trend (HR, 0.65; P = .055). Trying to investigate the result further, we conducted a validation study based on the SEER database, which also is nationwide. We included patients from 2004 through 2014 in the SEER database using the criteria of Tian et al.1 A total of 2201 patients finally were selected in our research, 934 of whom received PCRT and surgery, 336 of whom received POC, and 931 of whom underwent surgery alone. Pairwise 1:1 propensity score matching was performed to compare the survival outcomes among the 3 groups. It was shown that both the PCRT and the POC groups experienced a survival benefit compared with the group treated with surgery alone. However, there was no statistically significant difference noted with regard to the overall survival or cancer-specific survival between the PCRT and the POC groups. We also conducted a subgroup analysis using Cox regression. Within the population of patients with T3 to T4 disease, the PCRT group was found to have significantly improved prognosis compared with the surgery-alone group (HR, 0.44; 95% CI, 0.34-0.58 [P < .001]). Compared with the POC group, the result indicated a survival advantage for PCRT (HR, 0.74; 95% CI, 0.54-1.02 [P = .07]), although statistical significance was not achieved. In addition, it was shown that the PCRT group had a significantly better prognosis than both the POC and surgery-alone groups among patients with T3 to T4 disease and with positive lymph nodes (HRs of 0.65 and 0.44, respectively [P = .02 and P < .001, respectively]). Based on the above evidence, although the contradiction between the study by Tian et al1 and the previous ones remains difficult to explain, it is rational to assume that patients with advanced disease benefit more from radiotherapy. Thus, instead of concluding that radiotherapy may increase the risk, we believe a subgroup analysis is needed. In addition, the description of the tumor stage and patients' characteristics after propensity score matching may facilitate further discussion. No specific funding was disclosed. The authors made no disclosures.

Successful treatment of intractable ulceration associated with dermatomyositis by debridement and the skin implantation of an artificial dermis sheet

Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study.

Survival benefit of local consolidative therapy for patients with single-organ metastatic pancreatic cancer: a propensity score-matched cross-sectional study based on 17 registries

Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients with Synchronous Bone Metastasis.

Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis

Survival benefit of combined immunotherapy and chemoradiotherapy in locally advanced unresectable esophageal cancer: an analysis based on the SEER database

The survival impact of palliative radiotherapy on synchronous metastatic pancreatic ductal adenocarcinoma: metastatic site can serve for radiotherapy-decision

Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy

Patients with Gastroesophageal Junction Adenocarcinomas of an Advanced Stage May Benefit from Perioperative Chemoradiotherapy: A Validation Based on the Surveillance, Epidemiology, and End Results Database

Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy

Surgery and Combined Transplant with Chemotherapy Improve Survival for Patients with Liver Limited and Locally Advanced Intrahepatic Cholangiocarcinoma: a Seer Database Analysis

Chemoradiotherapy is Associated with Improved Survival for Resected Pancreatic Adenosquamous Carcinoma: a Retrospective Cohort Study from the SEER Database

Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV.

Liver Metastasis–Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients

A retrospective analysis of patients with unresectable pancreatic cancer treated with combined transarterial intervention and three dimensional conformal radiotherapy

Survival Outcomes for Metastatic Prostate Cancer Patients Treated With Radical Prostatectomy or Radiation Therapy: A SEER-based Study

[Apropos of 4 cases of congenital absence of the left lobe of the liver. Possible surgical consequences].

Effect of Neoadjuvant Radiotherapy on Survival of Non-Metastatic Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis

The Survival Benefit from the Addition of Radiation to Chemotherapy in Gastric Cancer Patients Following Surgical Resection.

Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database.

Survival Analysis of TACE Monotherapy Vs. Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma: A Retrospective Cohort Study